119 related articles for article (PubMed ID: 8705091)
1. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study.
Batista J; Stüsser R; Saéz F; Pérez B
Int J Clin Pharmacol Ther; 1996 Mar; 34(3):134-7. PubMed ID: 8705091
[TBL] [Abstract][Full Text] [Related]
2. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
[TBL] [Abstract][Full Text] [Related]
3. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients.
Stüsser R; Batista J; Padrón R; Sosa F; Pereztol O
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):469-73. PubMed ID: 9760006
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.
Mirkin A; Mas R; Martinto M; Boccanera R; Robertis A; Poudes R; Fuster A; Lastreto E; Yañez M; Irico G; McCook B; Farré A
Int J Clin Pharmacol Res; 2001; 21(1):31-41. PubMed ID: 11708573
[TBL] [Abstract][Full Text] [Related]
6. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
9. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
[TBL] [Abstract][Full Text] [Related]
10. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
11. Concomitant use of policosanol and beta-blockers in older patients.
Castaño G; Mas R; Gámez R; Fernández J; Illnait J; Fernández L; Mendoza S; Mesa M; Gutiérrez JA; López E
Int J Clin Pharmacol Res; 2004; 24(2-3):65-77. PubMed ID: 15689053
[TBL] [Abstract][Full Text] [Related]
12. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
Cubeddu LX; Cubeddu RJ; Heimowitz T; Restrepo B; Lamas GA; Weinberg GB
Am Heart J; 2006 Nov; 152(5):982.e1-5. PubMed ID: 17070175
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
Castaño G; Más R; Fernández L; Illnait J; Mendoza S; Gámez R; Fernández J; Mesa M
Drugs Exp Clin Res; 2005; 31 Suppl():31-44. PubMed ID: 16444910
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Crespo N; Illnait J; Más R; Fernández L; Fernández J; Castaño G
Int J Clin Pharmacol Res; 1999; 19(4):117-27. PubMed ID: 10939029
[TBL] [Abstract][Full Text] [Related]
15. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
Más R; Castaño G; Illnait J; Fernández L; Fernández J; Alemán C; Pontigas V; Lescay M
Clin Pharmacol Ther; 1999 Apr; 65(4):439-47. PubMed ID: 10223782
[TBL] [Abstract][Full Text] [Related]
16. Effect of sugar cane policosanol on lipid profile in primary hypercholesterolemia.
Francini-Pesenti F; Beltramolli D; Dall'acqua S; Brocadello F
Phytother Res; 2008 Mar; 22(3):318-22. PubMed ID: 18167048
[TBL] [Abstract][Full Text] [Related]
17. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia.
Canetti M; Moreira M; Mas R; Illnait J; Fernandez L; Fernandez J; Diaz E; Castano G
Int J Clin Pharmacol Res; 1995; 15(4):159-65. PubMed ID: 8871266
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
Alcocer L; Fernández L; Campos E; Más R
Int J Tissue React; 1999; 21(3):85-92. PubMed ID: 10645516
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.
Castaño G; Fernández L; Mas R; Illnait J; Fernández J; Mesa M; Alvarez E; Lezcay M
Int J Clin Pharmacol Res; 2002; 22(2):55-66. PubMed ID: 12503776
[TBL] [Abstract][Full Text] [Related]
20. Sugar cane policosanol failed to lower plasma cholesterol in primitive, diet-resistant hypercholesterolaemia: a double blind, controlled study.
Francini-Pesenti F; Brocadello F; Beltramolli D; Nardi M; Caregaro L
Complement Ther Med; 2008 Apr; 16(2):61-5. PubMed ID: 18514906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]